eIF4E/eIF4G Interaction Inhibitor, 4EGI-1Amplifies TRAIL-induced apoptosis via down-regulation of FLIPS/L and induction of DR5

eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 (CAS 315706-13-9)

eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 | CAS 315706-13-9 is rated 5.0 out of 5 by 1.
  • y_2019, m_11, d_12, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202597, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 110ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Application: Amplifies TRAIL-induced apoptosis via down-regulation of FLIPS/L and induction of DR5
CAS Number: 315706-13-9
Purity: >95%
Molecular Weight: 451.3
Molecular Formula: C18H12Cl2N4O4S
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

eIF4E/eIF4G Interaction Inhibitor, 4EGI-1, has been shown to amplify TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis via down-regulation of FLIPS/L and induction of DR5. These characteristics of the compound seem to be independent of it's ability to inhibit cap-dependent protein translation which is caused by disruption of the eIF4E/eIF4G association through binding to eIF4E. It has been shown that while 4EGI-1 displaces eIF4G from eIF4E, it consequentially enhances 4E-BP association both in vivo and in vitro. 4E-BPs regulated the eIF4E/eIF4G complex which has a central role in the regulation of gene expression at the level of translation initiation.


References

1. Moerke, N.J., et al. 2007. Cell. 128: 257-267. PMID: 17254965
2. Carroll, M. 2009. Blood. 114: 1458-1459. PMID: 19696209
3. Tamburini, J., et al. 2009. Cell Cycle. 8: 3893-3899. PMID: 19934662
4. Fan, S., et al. 2010. Neoplasia. 12: 346-356. PMID: 20360945

Physical State :
Solid
Solubility :
Soluble in DMSO.
Storage :
Store at 4° C
IC50 :
levels of c-Myc and Bcl-xL: IC50 = ~25 µM (Jurkat cells)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
SMILES :
C1=C(C(=CC(=C1)C2CSC(=N2)N\\N=C(\\CC3=CC=CC=C3N(O)O)C(=O)O[H])Cl)Cl

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

eIF4E/eIF4G Interaction Inhibitor, 4EGI-1  Product Citations

See how others have used eIF4E/eIF4G Interaction Inhibitor, 4EGI-1. Click on the entry to view the PubMed entry .

Citations 1 to 10 of 11 total

PMID: # 29861391  Wu, Z. et al. 2018. Cell Metab. 28: 130-144.e7.

PMID: # 29158530  Kim, WK. et al. 2017. Sci Rep. 7: 15833.

PMID: # 27822137  Kerr, LT. et al. 2016. Sarcoma. 2016: 3484673.

PMID: # 24587347  Feng, C. et al. 2014. PLoS ONE. 9: e90388.

PMID: # 23770856  Jiang, CC. et al. 2014. Oncogene. 33: 2577-88.

PMID: # 24952648  Ludwig, LS. et al. 2014. Nat. Med. 20: 748-53.

PMID: # 24971752  Chen, LZ. et al. 2014. PLoS ONE. 9: e100457.

PMID: # 25025927  Zhang, Z. et al. 2014. Cancer Lett. 352: 203-13.

PMID: # 23665580  Durand, S. et al. 2013. Nat. Struct. Mol. Biol. 20: 702-9.

PMID: # 23633452  Willimott, S. et al. 2013. Clin. Cancer Res. 19: 3212-23.

Citations 1 to 10 of 11 total

What is the solubility of this product?

Asked by: SCchem16
Thank you for your question. This chemical, eIF4E/eIF4G Interaction Inhibitor, 4EGI-1 (CAS 315706-13-9), is soluble to 100 mM in DMSO.
Answered by: Chemical Support 2
Date published: 2017-04-07
  • y_2019, m_11, d_12, h_16CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.1
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_202597, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 116ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Yi Yi, T. et al. (PubMed 25115391) found that 4EGI-1 (eIF4E/eIF4G Interaction Inhibitor) effectively inhibits breast cancer stem cells (CSCs) through selectively reducing translation persistent in breast (CSCs). Furthermore, 4EGI-1 selectively inhibits translation of mRNAs encoding NANOG, OCT4, CXCR4, c-MYC and VEGF in breast CSC tumors. -SCBT Publication Review
Date published: 2015-03-16
  • y_2019, m_11, d_12, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.1
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_202597, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 4ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.